These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 26323996

  • 1. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
    Ma Z, Liu W, Zeng J, Zhou J, Guo P, Xie H, Yang Z, Zheng L, Xu S, Wang X, Chang LS, He D, Li L.
    Oncol Rep; 2015 Nov; 34(5):2461-8. PubMed ID: 26323996
    [Abstract] [Full Text] [Related]

  • 2. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
    Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P, Wang X, He D, Zeng J.
    Int J Mol Sci; 2015 Apr 15; 16(4):8415-29. PubMed ID: 25884331
    [Abstract] [Full Text] [Related]

  • 3. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Chang HR, Chen PN, Yang SF, Sun YS, Wu SW, Hung TW, Lian JD, Chu SC, Hsieh YS.
    Mol Carcinog; 2011 Oct 15; 50(10):811-23. PubMed ID: 21574189
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W, Han W, Fan T, Wang X, Cheng Z, Wan B, Chen J.
    Biomed Pharmacother; 2018 Nov 15; 107():1505-1513. PubMed ID: 30257368
    [Abstract] [Full Text] [Related]

  • 7. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M, Si S, Li Y, Schoen S, Xiao GQ, Li X, Teh BT, Wu G, Chen J.
    Oncotarget; 2015 Oct 20; 6(32):32761-73. PubMed ID: 26418749
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
    Ubai T, Azuma H, Kotake Y, Inamoto T, Takahara K, Ito Y, Kiyama S, Sakamoto T, Horie S, Muto S, Takahara S, Otsuki Y, Katsuoka Y.
    Anticancer Res; 2007 Oct 20; 27(1A):75-88. PubMed ID: 17352219
    [Abstract] [Full Text] [Related]

  • 10. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S.
    Oncotarget; 2017 May 02; 8(18):30151-30161. PubMed ID: 28404914
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC, Heo JH, Jeon JY, Choi HJ, Jo AR, Kim SW, Kwon HJ, Hong SJ, Han KS.
    BMC Cancer; 2015 Jan 23; 15():19. PubMed ID: 25613585
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 23; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 15. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY, Lv YF, Lu L, Cai L.
    Anticancer Drugs; 2014 Nov 23; 25(10):1192-200. PubMed ID: 25075795
    [Abstract] [Full Text] [Related]

  • 16. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, Zhao H, Zhao L, Jiang Q, Yu Z, Jin F, Mi X, Wang E, Cui Z, Fu L, Chen J, Wei M.
    Clin Sci (Lond); 2015 Nov 23; 129(9):809-22. PubMed ID: 26201092
    [Abstract] [Full Text] [Related]

  • 17. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway.
    Yao Y, Zhou D, Shi D, Zhang H, Zhan S, Shao X, Sun K, Sun L, Wu G, Tian K, Zhu X, He S.
    Biomed Pharmacother; 2019 Mar 23; 111():993-1004. PubMed ID: 30841479
    [Abstract] [Full Text] [Related]

  • 18. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model.
    Shanmugam MK, Rajendran P, Li F, Kim C, Sikka S, Siveen KS, Kumar AP, Ahn KS, Sethi G.
    Mol Carcinog; 2015 Oct 23; 54(10):971-85. PubMed ID: 24797723
    [Abstract] [Full Text] [Related]

  • 19. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways.
    Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC.
    J Cell Biochem; 2012 May 23; 113(5):1733-43. PubMed ID: 22213051
    [Abstract] [Full Text] [Related]

  • 20. Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells.
    Cho HJ, Suh DS, Moon SH, Song YJ, Yoon MS, Park DY, Choi KU, Kim YK, Kim KH.
    J Agric Food Chem; 2013 May 01; 61(17):4089-96. PubMed ID: 23570653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.